Canopy Growth Reports Improved Financials Despite Weak Stock Performance
In its first quarter of fiscal year 2027, Canopy Growth (NASDAQ: CGC) reported improved financial results with net revenue rising to $81.2 million CAD ($58.6 million), a 13% increase from the previous year's quarter. The company also noted higher gross margins and significant reductions in both net losses (-68%) and adjusted EBITDA losses (-59%). Despite these positive developments, Canopy Growth’s stock remains below $1 per share. The article highlights two key challenges affecting investor sentiment: delayed U.S. federal legalization progress for recreational marijuana and ongoing equity dilution due to the company's reliance on raising capital through at-the-market programs. Although medical marijuana was rescheduled from Schedule I to III in April 2026, there has been little movement toward broader reforms that would allow Canopy Growth to export products into the U.S., which is critical for its growth strategy. Canopy’s share count increased significantly over the past year due to capital-raising efforts. With a current market cap of $394 million and an additional $200 million in potential funding from another ATM program, further dilution remains a concern.
